Commonwealth Equity Services, LLC Apellis Pharmaceuticals, Inc. Transaction History

Commonwealth Equity Services, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	SELL	$55.39 - $72.47 $124,572 - $162,985	-2,249 Reduced 31.38%	4,919 $289,000
Q4 2023 Feb 06, 2024	BUY	$37.14 - $64.82 $9,136 - $15,945	246 Added 3.55%	7,168 $429,000
Q3 2023 Oct 23, 2023	BUY	$23.65 - $89.22 $53,519 - $201,904	2,263 Added 48.57%	6,922 $263,000
Q2 2023 Aug 10, 2023	SELL	$76.68 - $93.31 $56,436 - $68,676	-736 Reduced 13.64%	4,659 $424,000
Q1 2023 May 11, 2023	BUY	$46.59 - $66.96 $251,353 - $361,249	5,395 New	5,395 $355,000

301

111M

2.63M

845K

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.61B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Commonwealth Equity Services, LLC with notifications on news.